Flexion Therapeutics ($FLXN), on the rebound after a stinging clinical setback, said its lead painkiller hit the mark in a Phase III trial in patients with ...

WOBURN, Mass., May 30, 2012 – Flexion Therapeutics, Inc. today reported that its lead osteoarthritis drug candidate, FX005, demonstrated significant pain relief over placebo at four weeks* in a Phase ...

For all the recent talk about pivots — to video, to paid models, to a new overarching ideology — most of the time such moves are an acknowledgment that things aren’t going all that swell. However, ...

Zilretta has several things going for it. It’s not an opioid painkiller—a plus at a time when opioid addiction is a nationwide issue. It appears to be safer in diabetics than standard-of-care steroid ...

Please provide your email address to receive an email when new articles are posted on . Flexion Therapeutics Inc. announced the full commercial launch of Zilretta for the management of pain associated ...

Zilretta could win FDA approval in knee pain later this year, and, if so, it could become the new standard of care. In this clip from The Motley Fool's Industry Focus: Healthcare podcast, Todd ...

BURLINGTON, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA) approved Zilretta™ (triamcinolone ...

With growing sales for Zilretta ® (triamcinolone acetonide extended-release injectable suspension), its first gene therapy candidate expected to generate clinical data before year’s end and another ...

BURLINGTON, Mass. and BURNABY, British Columbia, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) and Xenon Pharmaceuticals Inc. (Nasdaq:XENE) today announced that the ...

Flexion Therapeutics ' (NASDAQ: FLXN) Zilretta is awaiting an FDA approval decision. If the regulator gives it a green light, Zilretta could reduce the use of opiates and corticosteroids in treating ...